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Abstract 
Clinical trials of experimental treatments must be designed with primary endpoints 
that directly measure clinical benefit for patients. In many disease areas, the 
recognised gold standard primary endpoint can take many years to mature, leading 
to challenges in the conduct and quality of clinical studies. There is increasing 
interest in using shorter-term surrogate endpoints as substitutes for costly long-term 
clinical trial endpoints; such surrogates need to be selected according to biological 
plausibility, as well as the ability to reliably predict the unobserved treatment effect 
on the long-term endpoint.  A number of statistical methods to evaluate this 
prediction have been proposed; this paper uses a simulation study to explore one 
such method in the context of time-to-event surrogates for a time-to-event true 
endpoint.  This two-stage meta-analytic copula method has been extensively studied 
for time-to-event surrogate endpoints with one event of interest, but thus far has not 
been explored for the assessment of surrogates which have multiple events of 
interest, such as those incorporating information directly from the true clinical 
endpoint. We assess the sensitivity of the method to various factors including 
strength of association between endpoints, the quantity of data available and the 
effect of censoring.  In particular, we consider scenarios where there exist very little 
data on which to assess surrogacy. Results show that the two-stage meta-analytic 
copula method performs well under certain circumstances and could be considered 
useful in practice, but demonstrates limitations that may prevent universal use.  
Keywords: Surrogate Endpoint; Meta-Analysis; Time-to-progression; Progression-
free-survival; Oncology 
 
1. INTRODUCTION 
Over recent years, the pharmaceutical industry has become increasingly aware of 
the need to improve efficiency in the drug development process, through innovative 
clinical trial design, increased data sharing and focus on personalised healthcare. 
One important factor in this process is the choice of clinical trial primary endpoint, 
upon which direct evidence of clinical benefit is required. Within oncology diseases 
for example, this choice of endpoint has commonly been overall survival, being 
objective, reliable and easy to measure. However, demonstrating a clinical benefit in 
survival is becoming increasingly complex due to increasing survival times of 
patients, higher trial costs, increased availability of alternative therapies and public 
demand for quicker treatment availability. As such, many researchers are proposing 
to substitute long term clinical endpoints with shorter term surrogate endpoints that 
can be assessed in less time and with less cost. For example, a measure of tumour 
shrinkage, or a composite endpoint of disease progression and death, have often 
been used as substitutes for overall survival in the assessment of oncology 
treatments. Use of these endpoints allows treatments to be developed faster, and 
subsequently made more affordable for payers. This approach has seen increasing 
popularity, with many recent drug approvals based on so-called surrogate endpoints 
[1].  
In order to replace a long-term clinical trial endpoint with one or more surrogates, it is 
necessary to evaluate whether the unobserved clinical benefit of treatment on the 
established longer-term endpoint can be reliably predicted by the observed treatment 
benefit on the surrogate endpoint(s). Due to the potential variation in treatment 
benefit amongst different diseases, patient populations and disease-modifying 
mechanisms of new treatments, this evaluation must be conducted for each potential 
application of a surrogate endpoint. In many cases, access to data may be limited to 
a very small subset of comparable data, such as that collected during a single 
clinical development programme.  
Over the last 25 years there have been many contributions to the statistical literature 
with regard to methodology for evaluating surrogate endpoints. These include single-
trial hypothesis testing methods [2], approximation methods [3-7], as well as meta-
analytic methods combining data from multiple trials or subgroups within trials [8-17]; 
a useful summary can be found in the review article written by Weir and Walley [18], 
along with an updated version written by Ensor et al. [19]. In recent applications (as 
seen in [20], [21]), the two-stage meta-analytic copula method of Burzykowski et al. 
[12], an extension to the original two-stage meta-analytic method proposed by Buyse 
et al. for continuous endpoints [10], has frequently been used. Based on a meta-
analysis of many clinical trial datasets, this approach proposes surrogacy measures 
based on modelling the joint survival distribution of the two (surrogate and long-term 
clinical) endpoints.  
In the case of time-to-event surrogate and true clinical endpoints, investigation into 
the performance of this method has thus far been restricted to surrogate endpoints 
that have one outcome of interest, such as exploration of time-to-progression (TTP) 
as a surrogate for overall survival (OS) in oncology studies. In reality, in order to 
maximise the number of events, decrease clinical trial durations and improve the 
clinical relevance of endpoints, alternative endpoints that consider multiple events of 
interest are commonly used to assess the clinical benefit of new therapies. Such 
endpoints, including progression-free survival (PFS), may also incorporate 
information from both a shorter-term and the true clinical endpoint. PFS is a 
commonly used endpoint in oncology studies and has been used as the basis for 
regulatory approval in a number of disease areas. 
An alternative surrogacy evaluation approach has been proposed for endpoints that 
capture multiple events of interest, such as PFS, through the use of a semi-
competing risks framework [22]. However, this method is based on separation of the 
surrogate endpoint into the individual events of interest, and resulting surrogacy 
evaluations may then not reflect how the commonly defined surrogate endpoint 
would behave when used in a new clinical study. Whilst the separation of events 
may offer benefit in some settings, this is not considered a suitable approach when 
assessing surrogate endpoints that have strong clinical and regulatory understanding 
and acceptance as measures of clinical benefit, such as PFS in oncology settings.  
In this paper, a simulation study is used to assess the performance of the two-stage 
meta-analytic copula method in the evaluation of two commonly used time-to-event 
endpoints (time-to-progression and progression-free survival) as surrogates for 
overall survival in the specific example of oncology clinical trials, for the case where 
there are limited data available on which to base surrogacy decisions. The aim is to 
reflect the use of the method from a pharmaceutical industry perspective, where 
there exist data from a limited number of small-sized clinical trials only, and it is 
desirable to determine whether a short-term surrogate endpoint can be used in 
subsequent confirmatory trials. Although the endpoints here are examples of those in 
oncology clinical trials, the investigation is applicable to any setting where a potential 
surrogate endpoint also captures data relevant to the true clinical endpoint.  The 
performance of the method has been assessed previously through simulation studies 
[23], including for small sample sizes [24], however these studies have focused on 
the scenario where the surrogate endpoint is defined as the time to one particular 
event of interest, independent of the true clinical endpoint. The impact of using a 
surrogate endpoint that is defined as the time to either a short-term event or the true 
clinical event of interest will therefore be assessed here. 
Section 2 contains brief details of the surrogacy method under exploration in this 
study and Section 3 describes the set-up of the simulations, including two different 
underlying data structures, the two different surrogate endpoints and various 
combinations of other factors of interest. Results can be found in Section 4, and 
Section 5 discusses the findings and makes recommendations for future use of the 
method. 
 
2. TWO-STAGE META-ANALYTIC COPULA MODEL 
In order to thoroughly assess a potential surrogate endpoint, Burzykowski et al. [25] 
recommend to explore two levels of prediction; the ability to predict the unobserved 
treatment effect on the established long-term endpoint given the observed treatment 
effect on the surrogate (trial-level surrogacy), and the ability of the surrogate to 
predict the actual outcome for a given patient, after adjusting for the treatment 
assignment (individual-level surrogacy). It is desirable for a surrogate endpoint to 
perform well at both of these levels, in order to provide confidence in its use as a 
substitute endpoint in further clinical development.  
The two-stage meta-analytic copula method proposed by Burzykowski et al. [12] 
assesses both levels of surrogacy through parameters of the joint survival 
distribution of the surrogate and long-term (true) endpoints. Using a copula model, 
specification of the joint survival distribution is achieved using the marginal survival 
functions of each variable, together with a function which relates the underlying 
dependence between them. Surrogacy is evaluated through a two-stage procedure, 
where stage one fits the copula to the data in order to obtain maximum likelihood 
estimates of treatment effects within each trial, as well as the level of dependence 
between the endpoints, from which an individual-level measure of surrogacy is 
derived. Stage two uses random effects modelling to calculate the coefficient of 
determination between the estimates of the treatment effects, and this is used as the 
trial-level measure of surrogacy.  
Suppose there exist data from 𝑖 = 1, . . . , 𝑁 trials each containing 𝑗 = 1, . . . , 𝑛 subjects 
with surrogate and true endpoint outcomes 𝑆𝑖𝑗 and 𝑇𝑖𝑗 respectively, for patient 𝑗 in 
trial 𝑖. Then, the general form of the joint survival function of the two endpoints is 
defined as 
𝑆(𝑠, 𝑡) = 𝑃(𝑆𝑖𝑗 ≥ 𝑠, 𝑇𝑖𝑗 ≥ 𝑡) =  𝐶𝜃 {𝑆𝑆𝑖𝑗(𝑠), 𝑆𝑇𝑖𝑗(𝑡)}, 
with 𝑠, 𝑡 ≥ 0, 𝜃 > 1, where 𝑆𝑆𝑖𝑗 and 𝑆𝑇𝑖𝑗  are the marginal survival functions of the 
surrogate and true endpoints respectively and 𝐶𝜃 is a bivariate distribution function 
on [0,1]2 with uniform margins. This distribution function is based on a copula 
function, describing the strength of association between the two endpoints through 
the parameter 𝜃. For some copula functions, 𝜃 can be directly interpreted as an 
association measure, whereas for other copula models it can be transformed to 
another measure, such as Kendall's 𝜏 [26], to ease interpretability and allow 
comparison between models. As such, Kendall's 𝜏 is the chosen estimator of 
individual-level surrogacy for the proposed two-stage meta-analytic copula surrogacy 
method. There are various options for choice of copula function [23], one of which is 
the Clayton copula, a one-parameter function chosen for simplicity. Based on this 
copula, the joint survival function is defined as 
 
𝐶𝜃 (𝑆𝑆𝑖𝑗(𝑠), 𝑆𝑇𝑖𝑗(𝑡)) = (𝑆𝑆𝑖𝑗(𝑠)
1−𝜃 + 𝑆𝑇𝑖𝑗(𝑡)
1−𝜃 − 1)
1
1−𝜃
,    𝜃 > 1. 
(1) 
 
Marginal survival functions for S and T, 𝑆𝑆𝑖𝑗(𝑠) and 𝑆𝑇𝑖𝑗(𝑡), are assumed to follow 
proportional hazards models with baseline hazards parametrically specified using a 
Weibull distribution, although these baseline hazards could also be left unspecified 
[23]. With this copula function, Kendalls' 𝜏 can be conveniently estimated using 
𝜏 =
𝜃−1
𝜃+1
. 
Once stage one of the procedure is applied and estimated trial-specific treatment 
effects on surrogate and true endpoints, (𝛼𝑖, 𝛽𝑖) respectively, are available, the 
second stage of the evaluation process can be performed by assuming a reduced 
random-effects model for these treatment effects: 
(
𝛼𝑖
𝛽𝑖
) = (
𝛼
𝛽) +  (
𝑎𝑖
𝑏𝑖
), 
where (𝛼, 𝛽) are fixed treatment effects, and the random effects (𝑎𝑖, 𝑏𝑖) are assumed 
to follow a zero-mean normal distribution with variance-covariance matrix 
𝐷 = (
𝑑𝑎𝑎 𝑑𝑎𝑏
𝑑𝑎𝑏 𝑑𝑏𝑏
). 
The trial-level measure of surrogacy is then estimated as 
 
 
A value of 𝑅𝑡𝑟𝑖𝑎𝑙
2  close to one would suggest that almost all of the variability in the 
treatment effect on the true endpoint is explained by the treatment effect on the 
surrogate, whereas a value close to zero would suggest that knowledge of the 
treatment effect on the surrogate explains little of the variation in the treatment effect 
on the true endpoint. 
Burzykowski et al. [12] discuss bias introduced into the trial-level 𝑅2 in equation (2), 
caused by the estimation error of the treatment effects coming from stage one of the 
model. In order to reduce this bias, the method proposed by van Houwelingen et al. 
[27] is suggested to provide an adjusted version of the trial-level surrogacy measure. 
However, it is noted that these adjusted estimators are often not available due to 
non-convergence and inadmissible estimates (outside of [0,1]), which therefore 
precludes their use in practice [23]. Although alternative approaches have been 
proposed [28], these adjusted measures are not further explored in our study as they 
are limited to estimation of 𝑅𝑡𝑟𝑖𝑎𝑙
2  only and it is our intention to assess both individual 
 
𝑅𝑡𝑟𝑖𝑎𝑙
2 =
𝑑𝑎𝑏
2
𝑑𝑎𝑎𝑑𝑏𝑏
. 
(2) 
and trial-level surrogacy in a consistent framework. The application of the two-stage 
meta-analytic copula method in this study is performed making use of publicly 
available code [29]. 
A positive feature of the two-stage meta-analytic copula method is that it can be 
based on any choice of copula function, and indeed Burzykowski et al. [12] describe 
the importance of selecting an appropriate copula based on the goodness of fit, 
suggesting a number of ways that this can be done. To explore how the choice of 
copula can impact interpretation of results, we consider two scenarios in our study. 
First, we consider performance of the surrogacy method under ideal conditions, 
where there is no model misspecification and the data are generated to have the 
same dependence structure assumed by the model. Further to this, we assess the 
reliability of results when there is model misspecification, by generating data using a 
different copula function with different underlying data structure to the model being 
applied.  
Renfro et al. [30] also explore the impact of different dependence structures, 
assessing performance of the two-stage meta-analytic copula method when the 
underlying data are generated using a Clayton copula constructed using cumulative 
distribution functions (CDF) instead of survival functions.  These two functional 
constructs allow the same copula function to reflect different dependence structures, 
thereby assessing the performance of the method in the presence of misspecified 
dependence. Our work differs from this concurrent work in that we maintain use of 
the survival implementation of the copula function and assess how results are 
affected when the surrogate endpoint includes information directly reflecting the true 
clinical endpoint. We also assume considerably smaller sample sizes, and explore 
the impact of medium-high censoring across all scenarios. 
2.1. MOTIVATING EXAMPLE 
In order to see how the two-stage meta-analytic copula surrogacy method can be 
applied in practice, we have used it to assess surrogacy within the context of a 
Phase III study of Herceptin plus chemotherapy versus chemotherapy alone in the 
treatment of HER2 positive advanced gastric cancer [31]. The primary analysis of 
this study included 584 patients who were randomly assigned to receive one of two 
study treatments.  The primary endpoint of the study was overall survival, with PFS 
included as a secondary endpoint. An interim analysis of OS was performed after 
75% of the required events had been observed, and at this time the treatment 
difference (hazard ratio 0.74, 95% confidence interval [CI] 0.60-0.91, median OS of 
13.8 versus 11.1 months in the experimental and control arms respectively) was 
sufficient to cross the pre-specified stopping boundary. The PFS result was 
consistent with that of OS, demonstrating evidence of a statistically significant benefit 
from treatment with experimental therapy compared to control therapy (median PFS 
6.7 months versus 5.5 months, hazard ratio 0.71 [95% CI 0.59-0.85]). 
In practice, data from multiple studies would be available to assess surrogacy and 
each study would represent an individual unit for analysis. However, in this example 
of a single clinical trial, the data are grouped according to country, with each country 
considered to represent a sub-study within the trial. Further discussion of this 
approach can be found in Renfro et al. [24]. Countries containing seven or fewer 
patients were grouped by geographical region to allow for parameter estimation; two 
countries were removed from analysis due to small numbers and the absence of a 
geographically similar country to combine with (n=4 and n=6 patients respectively). 
Based on the remaining dataset of 574 patients, results from the application of the 
surrogacy method show that the 𝑅𝑡𝑟𝑖𝑎𝑙
2  point estimate (0.57) likely does not support 
the use of PFS as a surrogate, whereas the individual-level surrogacy (𝜏 = 0.67) 
could be considered worthy of further investigation. 
 
3. SIMULATION STUDY 
As mentioned above, the two-stage meta-analytic copula method has previously 
been assessed via a simulation study [23]. However, this study was limited in that 
the impact of the underlying data-generation procedure was not considered, only one 
type of surrogate endpoint with one event of interest was used, and it was based on 
sample sizes that are not always realistic in practice. Additional studies designed to 
address some of these concerns have been conducted [24,30], however none have 
explored the impact on the joint modelling of using a surrogate endpoint that includes 
the true endpoint as an event of interest.  
The study presented in this paper addresses these concerns by exploring a 
comprehensive range of factors, as outlined in Table 1. 
Table 1: Simulation Scenarios 
Factor Scenarios 
Number of trials 4,6 
Patients per trial 80, 120, Mixed (50% each of 80,120) 
Surrogate Endpoint TTP, PFS 
Data Generation Clayton, Gumbel 
Trial-level association 0.2, 0.5, 0.8 
Individual-level association 0.2, 0.5, 0.8 
Censoring Rate (on 𝑇) 0%, 30%, 60% 
 
There are a number of aims of our study; the first is to determine how well the 
method performs when using a surrogate endpoint that combines multiple events of 
interest, including the event of interest for the true endpoint. In the original simulation 
study performed by Burzykowski et al. [12], the simulated data are constructed 
according to a time-to-progression scenario, where the surrogate is censored by 
occurrence of the true endpoint, rather than being considered an event. Our study 
generates data according to both time-to-progression (TTP) and progression-free 
survival (PFS) algorithms, to determine whether there is any impact of using a 
surrogate that also includes information relating to the true endpoint. In this setting, 
PFS is defined as the time to the earliest of disease progression or death. This is 
considered highly relevant since many of the applications of this surrogacy 
evaluation approach have been based on the use of composite endpoints such as 
PFS, yet the method has not been explored for this setting via simulation. 
The second aim of our study is to assess the performance of the method when there 
are a very small number of trials with very few patients. Although small-sample 
simulation studies were performed by Burzykowski et al. [12], the authors considered 
10 or 20 trials containing 50, 100 or 200 subjects, which may be considered too 
many trials compared to those available within a single clinical development plan. 
Further studies of the two-stage meta-analytic copula method have explored small 
sample sizes [24], however these studies did not examine in detail the impact of 
censoring or changes in the underlying trial and individual-level surrogacy. Our study 
therefore considers 4-6 clinical trials containing 80-120 subjects each, estimating 
both 𝜏 and 𝑅𝑡𝑟𝑖𝑎𝑙
2 . 
One of the most important factors in setting up this simulation study is ensuring that 
the individual and trial-level association can be accurately controlled. In order to 
achieve this, Burzykowski et al. [12] control individual-level association through use 
of a copula model for data generation, with a chosen copula dependence parameter 
reflecting the strength of surrogacy. Using the copula parameter allows for clear and 
simple controlling of the individual-level dependence between endpoints, however, 
since our application of the two-stage meta-analytic copula method is based on the 
Clayton copula model, our study uses the Clayton as well as the Gumbel copula 
functions for data generation in order to assess the impact of model misspecification. 
These two copula functions assume different underlying dependence structures of 
the two endpoints, and are discussed further in Sections 3.1 and 3.2. In all cases, we 
construct the joint survival function using exponential survival functions as the 
marginal distributions of the two endpoints.  Inclusion of both of these data 
generation methods allows us to investigate how the two-stage meta-analytic copula 
method performs both under ideal conditions, and under model misspecification. 
Finally, the original simulation study investigating the two-stage meta-analytic copula 
method considered just 500 repetitions of the generated datasets, likely due to 
computational restrictions. Given the extensive list of parameters of interest in our 
study, which is summarised in Table 1, and the expected computation time, it was 
felt that the largest number of runs that could be achieved in a reasonable time-
frame was 5,000 per scenario. Simulations were run on a Windows 7 64-bit machine 
with 4GB RAM, using macros based on SAS ® software, Version 9 for Windows [32].  
As can be seen in Table 1, in addition to factors described above relating to the 
number and size of trials and type of endpoint, values of low (0.2), medium (0.5) and 
high (0.8) individual and trial-level surrogacy are considered, under varying 
proportions of censoring. Very few studies have considered low levels of association 
between endpoints, and those that have were either limited in the number of 
scenarios under detailed investigation [24] or were based on much larger sample 
sizes [30]. Additionally, although the range of treatment effects within trials is not of 
primary interest in this study, previous studies have shown variations in performance 
of the copula model under various ranges of effects, and so this was added as a final 
simulation parameter. Simulation parameters were chosen to reflect data 
characteristics similar to the motivating example.  
 
3.1. CLAYTON COPULA DATA GENERATION 
The Clayton copula function with marginal survival functions takes the specific form 
of equation (1), and to be consistent with Burzykowski et al. [23], the marginal 
survival functions are chosen to follow an exponential survival distribution. As 
described by Burzykowski et al. [23], trial-specific random effects are used to control 
the trial-level association, and in order to obtain draws of 𝑆𝑖𝑗 and 𝑇𝑖𝑗 from the joint 
survival function according to the Clayton copula, the conditional distribution method 
was applied [23, 33]. The algorithm draws two independent random variables from a 
Uniform(0,1) distribution, which are then transformed to be distributed according to 
the joint survival function defined by the copula function, with strength of 
dependence controlled using the copula dependence parameter. Once transformed, 
the two uniform random variables have the required shape and strength of 
association, and can be further transformed to survival outcomes according to the 
selected exponential marginal survivor functions. Based on these marginal functions, 
the joint survival function provides strong upper-tail dependence and weaker lower-
tail dependence (see [23] for details).  
The baseline hazards are chosen to reflect a scenario where the median value of the 
surrogate (5-6 months) is approximately half of that of the true endpoint (11-12 
months), therefore providing benefit in terms of the length of the study, and being 
consistent with the motivating example. The treatment effects are chosen such that 
the effect on S (hazard ratio ~0.67) is slightly stronger than that on T (hazard ratio 
~0.82), in order to reflect the potential influence of post-progression therapies and 
long-term follow-up. Censoring is applied by drawing an exponential random variable 
and comparing to the simulated event values, scaling the random value to control the 
proportion of censoring in the data (0%, 30% and 60%). Since our true endpoint is 
overall survival, the value of TTP as the surrogate is also censored by the true 
endpoint, if it occurs first. For PFS, when death occurs prior to progression the 
patient is considered to have an event at the time of death and additional censoring 
is not applied.  
Recall that although the copula parameter is used to control the level of dependence 
between the endpoints, it is not always interpretable as a measure of association. 
Therefore, Kendall's 𝜏 is used to select the required individual association between 
endpoints. For the Clayton copula, 𝜃 can be calculated directly from Kendall's 𝜏 
using 𝜃 =
1+𝜏
1−𝜏
, and so values of 𝜃 were set to 1.5, 3 and 9 in order to achieve `true' 
individual-level association of 0.2, 0.5 and 0.8 respectively. In order to achieve the 
required `true' trial-level association values of 0.2, 0.5 and 0.8, the covariance values 
of the trial-specific random effects were fixed as in [23]. 
3.2. GUMBEL COPULA DATA GENERATION 
Previous simulation studies of the two-stage meta-analytic copula method use the 
same copula function to both simulate data and assess surrogacy. In order to 
investigate whether this can lead to a favourable bias in performance of the copula 
method, this paper also presents results from simulations where data are generated 
according to the Gumbel copula. In particular, this approach helps to investigate 
whether the choice of copula family being applied to the data impacts this method of 
assessing surrogacy. Based on the joint survival function, the dependency structure 
of the Gumbel copula is different to the Clayton copula in that it exhibits strong lower-
tail dependence (i.e. earlier event times), whereas the Clayton exhibits strong upper-
tail dependence (i.e. later event times). For the two endpoints, S and T, the form of 
the Gumbel model is  
 
𝐶𝜃 (𝑆𝑆𝑖𝑗(𝑠), 𝑆𝑇𝑖𝑗(𝑡)) = exp [− {(− log 𝑆𝑆𝑖𝑗(𝑠))
1
𝜃
+ (− log 𝑆𝑇𝑖𝑗(𝑡))
1
𝜃
}
𝜃
]  
(3) 
 
for 0 < 𝜃 < 1, where 𝑆𝑆𝑖𝑗(𝑠) and 𝑆𝑇𝑖𝑗(𝑡) again represent exponential marginal survivor 
functions for S and T, respectively. The conditional distribution method used to 
generate data from the Clayton copula cannot be so easily used to generate from the 
Gumbel copula since the first derivative of the Gumbel copula is not invertible, 
however the R copula package contains a function to generate correlated random 
variables according to the Gumbel copula. Since our simulation study makes use of 
available macros based on SAS software to conduct copula modelling, our data were 
instead generated using the mixtures of powers algorithm described by Trivedi and 
Zimmer [34]. Testing of both data generation methods provided datasets with 
comparable characteristics. The first step of the algorithm is to generate a random 
variable, 𝛾, from a positive stable distribution, as well as two uniform variables from 
𝑈(0,1), 𝑈𝑖𝑗 and 𝑉𝑖𝑗. These uniform variables are transformed using 𝛾 to be distributed 
according to the Gumbel copula, with the required individual-level association.   
In order to generate 𝛾, a uniform random variable 𝜂 was drawn from 𝑈(0, 𝜋), and 
together with the required association level 𝜃, this draw was used to generate a 
value 𝑧 according to 
𝑧 =
sin(𝜂(1 − 𝜃))(sin(𝜂𝜃))
𝜃
1−𝜃
sin(𝜂)
1
1−𝜃
 , 
which was then used to derive 𝛾 using a random variable, 𝜔, drawn from a standard 
exponential distribution, as 𝛾 = (
𝑧
𝜔
)
1−𝜃
𝜃
 . 
Using this value of 𝛾, 𝑈𝑖𝑗 and 𝑉𝑖𝑗 are transformed to be uniform variables which are 
distributed according to the Gumbel copula, using 
?̃?𝑖𝑗
0 = exp (− (
− log(𝑈𝑖𝑗)
𝛾
)
𝜃
) , 
?̃?𝑖𝑗
0 = exp (− (
− log(𝑉𝑖𝑗)
𝛾
)
𝜃
) . 
These two uniform random variables then have the required shape and strength of 
dependence of the Gumbel copula, and the joint survival function can be constructed 
by further transforming ?̃?𝑖𝑗
0  and ?̃?𝑖𝑗
0 to time-to-event draws, 𝑆𝑖𝑗 and 𝑇𝑖𝑗, using marginal 
exponential survivor functions. Censoring was applied as described above. As with 
the Clayton copula, the required trial-level association is controlled within the 
covariance matrix 𝐷 used in the marginal survivor functions, setting 𝜌 equal to the 
square-root of the required association level. Here, the copula parameter 𝜃 can be 
calculated directly from Kendall's 𝜏 using 𝜃 = 1 − 𝜏, so values of 𝜃 were set to 0.8, 0.5 
and 0.2 in order to achieve `true' individual-level association of 0.2, 0.5 and 0.8 
respectively.  
3.3. CHOICE OF SIMULATION PARAMETERS 
To ensure the most realistic representation of true clinical trial data, certain scenarios 
were implemented within the data generation algorithm. Firstly, to reflect the impact 
of long-term follow-up of patients, in particular with respect to the requirement for 
extended monitoring of disease progression, it was assumed that approximately 5% 
of subjects would be censored for the surrogate (TTP or PFS) earlier than their time 
of death. For the composite endpoint of progression and death (PFS), this means 
that the death event was not used for these 5% patients, which is considered a 
realistic representation of cases where there is no reliable estimate for the true time 
of disease progression, for example when there are multiple consecutive missing 
disease assessments, or if alternative therapy has been started prior to evidence of 
disease progression. 
For cases where OS was censored and the generated value of the surrogate was 
lower than OS, the surrogate was considered as an event 80% of the time. This 
allows approximately 20% of subjects to be censored for the surrogate earlier than 
the time of censoring of OS, representing scenarios where subjects withdraw 
consent from further medical procedures to determine disease status, or have 
disease assessments scheduled less frequently than other clinical trial visits. These 
factors are considered to reflect true clinical trial settings.  
 
4. RESULTS 
4.1. CONVERGENCE 
When using TTP as the surrogate endpoint, there were very few issues with 
convergence of the two-stage meta-analytic copula method, with a maximum non-
convergence rate of 1.12%, the majority of which occurred for low levels of true 
individual-level association. However, when PFS was used as the surrogate, non-
convergence was significantly worse, reaching as high as 61.3% for low individual 
association. In both cases, the non-convergence for medium-high levels of individual 
association was close to zero, and the issues were mainly found with the low level of 
true individual association, and this was consistent between the Clayton and Gumbel 
generated data. The results in this section are therefore based only on those runs 
that successfully converged, and those that did not converge were not replaced. 
Since there are approximately 2000 successful runs for even the worst cases of non-
convergence, it was felt that this was substantial enough to assess the performance 
of the method, recalling that previous simulation study to assess the copula used 
only 500 runs. On occasion there was also a lack of convergence caused by the 
choice of initial values. Following Burzykowski [23], when this occurred the result 
from the previous repetition was used, and a sensitivity analysis of available results 
showed that this was a reasonable approach, with no noticeable differences in the 
overall conclusion. 
4.2. INDIVIDUAL-LEVEL PERFORMANCE 
Figure 1 illustrates the estimated 𝜏 values across the simulation scenarios of interest. 
Each boxplot shows the range of estimated values across all runs, with the level of 
censoring along the 𝑥-axis and the true underlying individual level association on the 
𝑦-axis. Within the figure, the individual plots display results from the two-stage meta-
analytic copula method with Clayton data generation on the top row and Gumbel 
data generation on the bottom row, with TTP in the left column and PFS in the right 
column. Since there was little difference in varying the number of trials or sample 
size within trials, only the smallest sample sizes are presented to illustrate the worst-
case scenario (four trials of eighty patients). Results of larger sample sizes can be 
found in the Supplementary Material. Additionally, since there was little variation in 
results with varying true underlying trial-level association, the results presented here 
represent only scenarios with 𝑅𝑡𝑟𝑖𝑎𝑙
2 = 0.5. Results for varying values of 𝑅𝑡𝑟𝑖𝑎𝑙
2  can 
also be found in Supplementary Material. Horizontal dashed lines at 𝑦 = 0.2, 0.5, 0.8 
represent the true individual-level surrogacy being estimated by each set of three 
boxplots from left to right. 
 
As can be seen, the method performs reasonably well for the TTP scenarios using 
Clayton-generated data (Figure 1, top left). Consistent with the original simulation 
study of this method by Burzykowski [23], results were mostly estimated with low 
average relative bias (maximum 2.8%) despite the small sample sizes explored here, 
with median estimates lying directly on the respective reference lines. However, 
variability is relatively high for low-medium levels of association, particularly when 
there is a high level of censoring. Under the Gumbel data generation (Figure 1, 
bottom left), it is clear that the performance for TTP deteriorates, with slightly 
increased variability and a noticeable under-estimation under the presence of little to 
no censoring. Overall the maximum average relative bias is -38.1%, demonstrating 
that the method most often under-estimates the true level of association, and could 
therefore be interpreted as a slightly conservative estimate. However, this 
interpretation could be hampered by the increased variability. Reassuringly, true high 
levels of association are estimated with the lowest variability, providing confidence 
that a large estimated value does in fact correspond to high true association between 
endpoints.  
Whilst results for TTP appear reasonably robust and similar to previous studies, the 
change to use of PFS as the potential surrogate causes significant issues, even for 
the Clayton data generation which should reflect the most ideal scenario. In addition 
to the aforementioned convergence, there is substantial impact on the performance 
of the method in estimation of low to medium levels of individual-level surrogacy. 
Whilst good estimation of truly high association remains, in the little explored 
scenario of low levels of true association, the estimated 𝜏 could be as high as 0.7 for 
both data generation methods, which could lead to a false conclusion that PFS is 
predictive of overall survival. The large variability for the true low levels of 
association also leads to overlap between low and medium association levels, 
particularly under increased censoring, which hampers interpretation of estimates 
that lie within a medium-high range (0.4 – 0.7). For estimates even towards the 
upper limit of this range, it is not realistically possible to conclude that the true 
underlying association is higher than 0.2. This issue is exacerbated by increased 
censoring, and there was no improvement from testing with larger sample sizes. 
Interestingly, the issues introduced through inclusion of PFS as the surrogate have 
impacted both data generation methods in a similar way, although slightly more 
impact is seen for the Gumbel data than for the Clayton copula, as could be 
expected. 
 
4.3. TRIAL-LEVEL PERFORMANCE 
Figure 2 contains similar boxplots to those for individual-level surrogacy, with the 𝑦-
axis now representing true underlying trial-level surrogacy. As before, only results for 
the smallest sample sizes are presented (four trials with eighty patients), and the 
individual-level surrogacy is held at 𝜏 = 0.5. Since results were extremely similar 
between the two data generation methods, only results from the Clayton-generated 
data are presented here. 
 
When considering the ability to predict the treatment effect on the true endpoint 
given the observed treatment effect on the surrogate, it is evident that given the 
small sample sizes considered here, the method cannot be deemed appropriate for 
use in this setting. For both endpoints and both data generation methods, the 
surrogacy evaluation method performs poorly. Although the average estimated value 
is sometimes close to the true association level, and there is a slight trend upwards 
as the true underlying association increases, it is also quite often the case that the 
true association is over or under-estimated. Additionally, there is a large amount of 
variability in the results, with 𝑅𝑡𝑟𝑖𝑎𝑙
2  estimates lying across the entire unit interval. 
Finally, there appeared to be a slight dependence between the individual and trial 
level association, with increasing 𝑅𝑡𝑟𝑖𝑎𝑙
2  estimates with increased true individual 
association. In order to verify results of previous simulation studies carried out by 
Burzykowski et al. [12], additional simulations were run for larger samples containing 
20 trials of 500 patients. The results of these simulations suggested that estimation 
of 𝑅𝑡𝑟𝑖𝑎𝑙
2  could indeed be much improved through inclusion of a larger number of 
studies with larger sample sizes, if those data are available.  In summary, the 
method did not allow for clear data interpretation of 𝑅𝑡𝑟𝑖𝑎𝑙
2  and cannot be 
recommended for trial-level analysis of meta-analyses of the size investigated here. 
The use of study centres within studies as units for surrogacy evaluation has been 
investigated [24], and will be discussed further in Section 5 in the context of the 
scenarios explored in this study. 
 
5. DISCUSSION 
The main aim of this simulation study was to assess the performance of the two-
stage meta-analytic copula method with respect to use of a surrogate endpoint that 
combines information from a short-term and true clinical endpoint. In addition, it was 
of interest to evaluate estimation of trial and individual-level surrogacy for small 
samples, a scenario that is commonly faced by individual pharmaceutical companies 
wishing to increase efficiency in clinical development programmes through the use of 
surrogate endpoints. A large range of scenarios were considered, including varied 
sample sizes, varying strength of individual and trial-level surrogacy, and different 
levels of censoring. 
In line with the simulation study performed by Burzykowski [23], the two-stage meta-
analytic copula method performed well in estimating 𝜏 for the time-to-progression 
endpoint, with the level of variability reflecting the small sample sizes used in this 
study. The change in underlying data structure led to slight under-estimation, but 
overall the estimates were not alarmingly different to the true values, although 
variability was considerably high in some cases. At worst, the estimates could be 
considered as lower bounds of the true association.  
For diseases where a high proportion of patients will die before they experience 
disease progression, TTP is not considered a feasible choice of surrogate endpoint. 
In oncology drug development, for example, PFS is used much more commonly, 
since events accumulate faster, trials can be conducted in a shorter period of time 
and subjects who die without disease progression are not lost through censoring.  
The two-stage meta-analytic copula method is currently recommended for use with 
any time-to-event surrogate [23], but results from this study show that caution is 
required when considering endpoints that incorporate information from the true 
clinical endpoint (e.g. PFS) as a possible surrogate endpoint, since a true low (0.2) 
level of individual association has been shown to be estimated as high as 0.7 in our 
simulations. This would undoubtedly be convincing enough for a clinician to consider 
moving forward with use of the surrogate, which could lead to a poor Phase III 
design and ultimately results that do not support the benefit of the treatment under 
development. This over-estimation was observed even for the ideal case where 
there was no model misspecification. For this reason, the two-stage meta-analytic 
copula method cannot be considered suitable for assessing surrogacy of PFS from 
clinical trials of the size used in our study. That said, since PFS is defined as the 
earliest of disease progression and death, it acts as a composite of TTP and OS, 
and so an encouraging assessment of TTP as a surrogate endpoint could warrant 
further clinical development based on a PFS endpoint. We would therefore 
recommend this approach over an assessment of PFS alone for oncology studies. 
Other diseases areas, such as cardiovascular disease, may also use endpoints that 
combine multiple events of interest, and the findings from this study may therefore 
be applicable to these settings also.  
With reference to the case study presented in Section 2.1, the results of the 
simulations hamper the interpretation of the reasonably high estimate of 𝜏, as it is not 
possible to know whether the estimate reflects a truly high underlying association 
between endpoints, or over-estimation of low association. This illustrates the 
uncertainty in conclusions that can be drawn from the two-stage meta-analytic 
copula method when using PFS as the surrogate, particularly when aiming to 
evaluate surrogacy from small samples. 
Of course, in practice it is necessary to fully understand the underlying structure of 
the data before selecting a particular copula model to apply; Burzykowski et al. [12] 
provide details of the surrogacy method for a selection of different copula functions, 
and suggest that the choice of final model should be based on the one with best fit to 
the data. Results of our simulations, together with the work conducted by Renfro et 
al. [30], substantiate the need for careful selection of both the copula family and the 
dependence structure, showing by two different approaches that when the 
dependence structure of the data is different to that assumed by the model, results 
cannot be considered reliable.  Importantly, results from our study demonstrate that 
even under the ideal conditions, where the same survival copula function is used to 
generate and analyse the data, performance of the method in evaluating PFS as a 
surrogate endpoint is suboptimal and potentially misleading.  
Burzykowski et al. [12] note that one limitation of the copula model is that surrogate 
and true endpoints are treated symmetrically, so that either endpoint can be shorter 
or longer than the other. This is clearly not the case when considering overall 
survival as the true endpoint, and so the authors highlight that caution is 
recommended when interpreting results. However, it would appear from our study 
that there are additional complications with the joint modelling of PFS and OS which 
need to be explored further. The work of Renfro et al. [30] suggests that alternative 
modelling using a two-stage, rather than simultaneous, estimation procedure may 
improve the performance of the two-stage meta-analytic copula method. However, 
this improvement was not seen uniformly across all simulation settings and so further 
examination of this is needed to determine whether it can improve the current 
performance in the assessment of PFS as a surrogate for OS. A further option would 
be to consider an alternative method to model the joint distribution of the two 
endpoints, for example through use of a multi-state model [35]. As discussed 
previously, a semi-competing risks paradigm that accounts for the restriction of S 
being shorter than or the same as T has also been proposed [22], however this 
method separates the surrogate endpoint into the individual components. The 
suitability of this approach therefore depends on the clinical setting and the intended 
definition of the surrogate endpoint when used in subsequent confirmatory clinical 
studies. 
Importantly, it has been shown that with the limited numbers of trials explored in our 
study, the method cannot be considered appropriate for assessing the level to which 
the treatment effect on the surrogate can predict the unobserved treatment effect on 
the overall clinical endpoint (𝑅𝑡𝑟𝑖𝑎𝑙
2 ). From the pharmaceutical industry perspective, 
this suggests that when using this surrogacy assessment method, data from a 
limited number of small phase I-II clinical trials would generally not provide enough 
evidence to warrant use of the surrogate endpoint as a complete replacement of the 
true clinical endpoint in confirmatory phase III trials. To improve estimation, if there 
exist additional phase III data from similar indications, these could also be included 
in the surrogacy assessment, accepting the assumptions of generalisability of the 
treatment, doses, patient population and general study design characteristics. Our 
exploratory simulations of larger sample sizes suggested that inclusion of additional 
data could improve performance of the method, however it remains uncertain as to 
what could be considered a sufficient sample size, and unfortunately a large amount 
of data are not frequently available.  
Further to this, there are often discussions as to whether centres within trials could 
be used to maximise the number of data points for analysis when only a small 
number of trials are available. This approach has been studied for both continuous 
[25] and time-to-event endpoints [24].  Renfro et al. [24] make a recommendation 
that for time-to-event studies with a moderate (5-9) number of trials, analysis of R2trial 
should be conducted using both trial and centre as the units of analysis, with the 
measure based on trials being considered the primary measure for interpretation. 
The results of our study indicate that when there are available data from six trials, a 
measure of R2trial based on trials as units does not provide reliable conclusions. 
Additionally, even when there are only four trials available for analysis, the value of 
R2trial based on trials as units is considered key when making inferences about the 
true underlying strength of surrogacy [24], but based on the context explored in our 
study this would be very unreliable.  Finally, it is currently unclear whether analysis of 
surrogacy conducted for centres within trials would be considered appropriate by 
regulatory authorities. 
In summary, when applied to small sample sizes, the two-stage meta-analytic copula 
method proposed for the evaluation of time-to-event surrogates demonstrated poor 
performance in the assessment of PFS as a surrogate endpoint, but has shown 
encouraging results when assessing the ability of TTP to predict OS. We therefore 
recommend that when the desired surrogate endpoint is TTP, an assessment of 
individual-level surrogacy of time-to-progression is performed using this method. As 
noted by Burzykowski et al. [23] and Renfro et al. [30], exploration of different copula 
functions and dependence structures should be conducted, with the choice of final 
copula function being based on the best fit to the data under investigation. As has 
been demonstrated in our study with the Gumbel-generated data, the application of a 
copula model with different functional form to the available data can lead to 
suboptimal estimation. When PFS is the desired surrogate endpoint, the two-stage 
meta-analytic copula method must be used with caution, as it may lead to false 
conclusions that a short-term endpoint has value as a surrogate. Given similarities 
between TTP and PFS endpoints, we recommend that when PFS is of interest as a 
potential surrogate, a surrogacy evaluation of TTP is also conducted to determine 
whether results are consistent between the two.  
At the trial-level, a formal quantitative assessment using the two-stage meta-analytic 
copula method cannot be considered reliable for such a small number of trials (4-6). 
Less formally, treatment effects that appear consistent between endpoints across 
multiple trials may be considered as encouraging, however the question remains as 
to how strong this relationship needs to be before the surrogate can be accepted as 
a new standard endpoint in future trials. 
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